BSP Pharmaceuticals vs Catalent: CDMO Comparison
How does BSP Pharmaceuticals compare to Catalent for mRNA/LNP manufacturing?
Side-by-side comparison of BSP Pharmaceuticals and Catalent on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent has more FDA inspections on record (24 vs 1) — a deeper regulatory paper trail.
- BSP Pharmaceuticals carries a cleaner inspection mix — no OAI classifications versus 2 for Catalent.
- Catalent has 2 FDA warning letters on record; BSP Pharmaceuticals has none.
- Catalent maintains 18 MHRA / UK GMP certificates; BSP Pharmaceuticals does not.
On a 13-modality CDMO landscape, both BSP Pharmaceuticals and Catalent qualify as mRNA/LNP manufacturers; BSP Pharmaceuticals carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both BSP Pharmaceuticals and Catalent qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: BSP Pharmaceuticals vs Catalent
How does BSP Pharmaceuticals compare to Catalent for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, BSP Pharmaceuticals is 78/100 and Catalent is 69/100; BSP Pharmaceuticals has 1 FDA inspection on record vs 24 for Catalent; European coverage is 15 active EMA+MHRA certificates for BSP Pharmaceuticals vs 39 for Catalent. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, BSP Pharmaceuticals or Catalent?
BSP Pharmaceuticals has 1 FDA inspection on record (NAI 0 / VAI 1 / OAI 0) and 0 warning letters. Catalent has 24 FDA inspections on record (NAI 7 / VAI 15 / OAI 2) and 2 warning letters.
How do BSP Pharmaceuticals and Catalent compare on European GMP coverage?
BSP Pharmaceuticals holds 15 active EMA GMP certificates and 0 MHRA / UK certificates. Catalent holds 21 active EMA GMP certificates and 18 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for mRNA/LNP manufacturing — BSP Pharmaceuticals or Catalent?
Both BSP Pharmaceuticals and Catalent are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BSP Pharmaceuticals carries a Signal Score of 78/100 and Catalent carries 69/100 — a small lead for BSP Pharmaceuticals. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →